Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Crestor Pricing On Par With Lipitor; Pattern Could Repeat In U.S.

Executive Summary

AstraZeneca is unlikely to seek a premium price for Crestor when it is launched in the U.S., CEO Tom McKillop indicated on a July 24 earnings call

You may also be interested in...



AstraZeneca Crestor Should Be Withdrawn For Safety Risks – Public Citizen

Public Citizen is citing AstraZeneca's marketing efforts for Crestor as one reason FDA should rapidly withdraw the statin

AstraZeneca Crestor Should Be Withdrawn For Safety Risks – Public Citizen

Public Citizen is citing AstraZeneca's marketing efforts for Crestor as one reason FDA should rapidly withdraw the statin

AstraZeneca Crestor 10 mg Fixed Starting Dose Supported By Committee

Dosing for AstraZeneca's statin Crestor in the general population should start with a fixed dose of 10 mg, FDA's Endocrinologic & Metabolic Drugs Advisory Committee recommended July 9

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel